{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:03:13Z","timestamp":1759334593333,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006640","name":"Open Society Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006640","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jfo.2023.02.021","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T09:10:50Z","timestamp":1693386650000},"page":"1204-1211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictors of stoppage and recurrence of choroidal neovascularization with a Treat- Extend-Stop protocol: 4-year follow-up"],"prefix":"10.1016","volume":"46","author":[{"given":"G.","family":"Garay-Aramburu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Rodriguez-Feijoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Aldazabal-Echeveste","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"del Barrio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Eiras-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.P.","family":"Pi\u00f1ero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Larrauri-Arana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfo.2023.02.021_bib0175","doi-asserted-by":"crossref","first-page":"413","DOI":"10.4103\/0301-4738.36473","article-title":"Introduction, mechanism of action and rationale for anti-vascular endothelial growth factor drugs in age-related macular degeneration","volume":"55","author":"Kim","year":"2007","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.jfo.2023.02.021_bib0180","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/aos.14786","article-title":"Role of intraretinal and subretinal fluid on clinical and anatomical outcomes in patients with neovascular age-related macular degeneration treated with bimonthly, treat-and-extend and as-needed ranibizumab in the In-Eye study","volume":"99","author":"Saenz-de-Viteri","year":"2021","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jfo.2023.02.021_bib0185","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1136\/bjophthalmol-2019-314251","article-title":"Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study","volume":"104","author":"Gale","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2023.02.021_bib0190","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1001\/jamaophthalmol.2020.2685","article-title":"Safety and efficacy of different doses and regimens of faricimab vs ranibizumab in neovascular age-related macular degeneration: the AVENUE phase 2 randomized clinical trial","volume":"138","author":"Sahni","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jfo.2023.02.021_bib0195","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/bjophthalmol-2019-313907","article-title":"Safety and tolerability of ranibizumab in uni\/bilateral neovascular age-related macular degeneration: 12-month TWEYEs study","volume":"104","author":"Bandello","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2023.02.021_bib0200","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1136\/bjophthalmol-2019-314661","article-title":"Effect of posterior vitreous detachment on treat-and-extend versus monthly ranibizumab for neovascular age-related macular degeneration","volume":"104","author":"Waldstein","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2023.02.021_bib0205","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1001\/jamaophthalmol.2019.5540","article-title":"Efficacy of a treat-and-extend regimen with ranibizumab in patients with neovascular age-related macular disease: a randomized clinical trial","volume":"138","author":"Kertes","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jfo.2023.02.021_bib0210","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1001\/jamaophthalmol.2018.6776","article-title":"Effect of ranibizumab and aflibercept on best-corrected visual acuity in treat-and-extend for neovascular age-related macular degeneration: a randomized clinical trial","volume":"137","author":"Gillies","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jfo.2023.02.021_bib0215","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12886-016-0207-3","article-title":"The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration\u2014A phase IV randomised clinical trial with ranibizumab: the FLUID study","volume":"16","author":"Arnold","year":"2016","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.jfo.2023.02.021_bib0220","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2023.02.021_bib0225","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","article-title":"Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial","volume":"119","author":"Chakravarthy","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2023.02.021_bib0230","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.ophtha.2010.12.019","article-title":"Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study","volume":"118","author":"Holz","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2023.02.021_bib0235","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.ophtha.2009.09.002","article-title":"Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR","volume":"117","author":"Bressler","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2023.02.021_bib0240","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/eye.2010.147","article-title":"Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial","volume":"24","author":"Subramanian","year":"2010","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.jfo.2023.02.021_bib0245","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1097\/IAE.0000000000001318","article-title":"Intravitreal aflibercept in neovascular age-related macular degeneration with limited response to ranibizumab: a treat-and-extend trial","volume":"37","author":"Hatz","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2023.02.021_bib0250","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","article-title":"Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies","volume":"121","author":"Schmidt-Erfurth","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2023.02.021_bib0255","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1136\/bjophthalmol-2013-304736","article-title":"Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial)","volume":"98","author":"Wykoff","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2023.02.021_bib0260","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2023.02.021_bib0265","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/aos.13774","article-title":"Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of on-demand therapy every 4 or 8 weeks","volume":"97","author":"Amarakoon","year":"2019","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jfo.2023.02.021_bib0270","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1111\/aos.12119","article-title":"Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of injections every 4 weeks, 6 weeks and 8 weeks","volume":"91","author":"Lushchyk","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jfo.2023.02.021_bib0275","first-page":"CD012208","article-title":"Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular","volume":"2020","author":"Li","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"year":"2015","series-title":"American Society of Retina Specialists Annual Preferences and Trends Survey","key":"10.1016\/j.jfo.2023.02.021_bib0280"},{"key":"10.1016\/j.jfo.2023.02.021_bib0285","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1016\/j.ophtha.2016.07.012","article-title":"Treatment patterns and visual outcomes during the maintenance phase of treat-and-extend therapy for age-related macular degeneration","volume":"123","author":"Essex","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2023.02.021_bib0290","first-page":"296","article-title":"Recommended guidelines for use of intravitreal aflibercept with a treat-and-extend regimen for the management of neovascular age-related macular degeneration in the Asia-Pacific region: report from a consensus panel","volume":"6","author":"Koh","year":"2017","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"10.1016\/j.jfo.2023.02.021_bib0295","doi-asserted-by":"crossref","DOI":"10.1007\/s00417-021-05283-0","article-title":"Results of patients with neovascular age-related macular degeneration managed by a treat-extend-stop protocol","author":"Adrean","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jfo.2023.02.021_bib0300","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.oret.2017.07.009","article-title":"Recurrence rate of choroidal neovascularization in neovascular age-related macular degeneration managed with a Treat-Extend-Stop protocol","volume":"2","author":"Adrean","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.jfo.2023.02.021_bib0305","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12886-015-0018-y","article-title":"Two or more dexamethasone intravitreal implants as monotherapy or in combination therapy for macular edema in retinal vein occlusion: subgroup analysis of a retrospective chart review study","volume":"15","author":"Singer","year":"2015","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.jfo.2023.02.021_bib0310","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/IAE.0b013e318297f842","article-title":"Efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion (Shasta study)","volume":"34","author":"Capone","year":"2014","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2023.02.021_bib0315","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.oret.2016.12.004","article-title":"Randomized trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: 2-year results of the TREX-AMD study","volume":"1","author":"Wykoff","year":"2017","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.jfo.2023.02.021_bib0320","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/IAE.0000000000001923","article-title":"Exit strategy in a treat-and-extend regimen for exudative age-related macular degeneration","volume":"39","author":"Arendt","year":"2019","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2023.02.021_bib0325","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10384-020-00783-8","article-title":"Four-year outcome of aflibercept administration using a treat-and-extend regimen in eyes with recurrent neovascular age-related macular degeneration","volume":"65","author":"Tsunekawa","year":"2021","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.jfo.2023.02.021_bib0330","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/IAE.0000000000002446","article-title":"Rates of exudative recurrence for eyes with inactivated wet age-related macular degeneration on 12-week interval dosing with bevacizumab therapy","volume":"40","author":"Hwang","year":"2020","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2023.02.021_bib0335","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.oret.2021.03.010","article-title":"Recurrent neovascular age-related macular degeneration after discontinuation of vascular endothelial growth factor inhibitors managed in a treat-and-extend regimen","volume":"6","author":"Aslanis","year":"2022","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.jfo.2023.02.021_bib0340","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s00417-019-04360-9","article-title":"Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration","volume":"257","author":"Abdin","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"}],"container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551223003248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551223003248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:21:17Z","timestamp":1759260077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0181551223003248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0181551223003248"],"URL":"https:\/\/doi.org\/10.1016\/j.jfo.2023.02.021","relation":{},"ISSN":["0181-5512"],"issn-type":[{"type":"print","value":"0181-5512"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of stoppage and recurrence of choroidal neovascularization with a Treat- Extend-Stop protocol: 4-year follow-up","name":"articletitle","label":"Article Title"},{"value":"Journal Fran\u00e7ais d'Ophtalmologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfo.2023.02.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}